The information in this preliminary prospectus is not complete and may be changed. The
securities may not be sold until the registration statement filed with the Securities and Exchange Commission becomes effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in
any state where the offer or sale is not permitted.
SUBJECT TO COMPLETION, DATED NOVEMBER 14, 2022
PRELIMINARY PROSPECTUS
Up to 64,020,756 Shares of Common Stock
Up to 13,824,992 Shares of Common Stock Issuable Upon Exercise of Warrants
Up to 5,200,000 Warrants to Purchase Common Stock
This prospectus relates to the
issuance by us of an aggregate of up to 13,824,992 shares of common stock, which consists of (i) up to 5,200,000 shares of common stock that are issuable upon the exercise of 5,200,000 Private Warrants originally issued in a private placement
to the Sponsor in connection with the initial public offering of LGL and (ii) up to 8,624,992 shares of common stock that are issuable upon the exercise of 8,624,992 Public Warrants originally issued in the initial public offering of LGL. We
will receive the proceeds from any exercise of any Warrants for cash.
This prospectus also relates to the offer and sale from time to time by the selling
securityholders of (i) up to 64,020,756 shares of common stock, consisting of (a) up to 12,500,000 shares of common stock issued in a private placement pursuant to the Subscription Agreements entered into on March 15, 2021, (b) up to
2,904,375 shares of common stock issued in a private placement to the Sponsor in connection with the Founder Shares, (c) up to 5,200,000 shares of common stock issuable upon exercise of the Private Warrants and (d) up to 43,416,381 shares
of common stock (including up to 81,412 shares of common stock issuable pursuant to outstanding options, 7,465,923 shares of common stock issuable in connection with the vesting and settlement of restricted stock units, and 560,703 shares of common
stock that were issued as Earnout Shares (as defined below) on September 17, 2021) pursuant to that certain Amended and Restated Registration Rights Agreement, dated August 26, 2021, between us and the selling securityholders granting such
holders registration rights with respect to such shares and (ii) up to 5,200,000 Private Warrants. We will not receive any proceeds from the sale of shares of common stock or Warrants by the selling securityholders pursuant to this prospectus.
The selling securityholders may offer, sell or distribute all or a portion of the securities hereby registered publicly or through private transactions
at prevailing market prices or at negotiated prices. We will not receive any of the proceeds from such sales of the shares of common stock or Warrants, except with respect to amounts received by us upon exercise of the Warrants. We will bear all
costs, expenses and fees in connection with the registration of these securities, including with regard to compliance with state securities or blue sky laws. The selling securityholders will bear all commissions and discounts, if any,
attributable to their sale of shares of common stock or Warrants. See the section titled Plan of Distribution.
The common stock and
the Public Warrants are listed on the New York Stock Exchange under the symbols IRNT and IRNT.WS, respectively. On November 11, 2022, the last reported sale price of the common stock was $0.6476 per share and the last
reported sale price of the Public Warrants was $0.0699 per Warrant.
We are an emerging growth company as defined under U.S. federal
securities laws and, as such, have elected to comply with reduced public company reporting requirements. This prospectus complies with the requirements that apply to an issuer that is an emerging growth company.
Investing in our common stock involves risks. See the section entitled Risk Factors beginning
on page 10 of this prospectus and in the documents incorporated by reference herein to read about factors you should consider before buying our securities.
Neither the Securities and
Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus
is , 2022.